N-phenyl-4-pyridin-4-yl-2-thiazolamine profile

ID Source	ID
PubMed CID	746609
CHEMBL ID	573226
CHEBI ID	121118
SCHEMBL ID	1886135

Synonym
EU-0078223
HMS1688A12
CBMICRO_027191
smr000120371
MLS000527797 ,
phenyl-(4-pyridin-4-yl-thiazol-2-yl)-amine
OPREA1_138465
BIM-0027090.P001
CHEBI:121118
n-phenyl-4-pyridin-4-yl-1,3-thiazol-2-amine
CHEMBL573226
AKOS000565321
SCHEMBL1886135
HMS2191J05
DTAVDUKDVHWDGI-UHFFFAOYSA-N
n-phenyl-4-(4-pyridinyl)-1,3-thiazol-2-amine
SR-01000492482-1
sr-01000492482
n-phenyl-4-pyridin-4-yl-2-thiazolamine
Q27209364

Class	Description
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	30.1313	0.0072	15.7588	89.3584	AID588342
Nrf2	Homo sapiens (human)	Potency	12.5893	0.0920	8.2222	23.1093	AID624171
glp-1 receptor, partial	Homo sapiens (human)	Potency	7.9433	0.0184	6.8060	14.1254	AID624417
ATAD5 protein, partial	Homo sapiens (human)	Potency	18.3564	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	29.0929	0.0008	11.3822	44.6684	AID686978
Smad3	Homo sapiens (human)	Potency	22.3872	0.0052	7.8098	29.0929	AID588855
P53	Homo sapiens (human)	Potency	50.1187	0.0731	9.6858	31.6228	AID504706
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	28.1838	0.0355	20.9770	89.1251	AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	1.9953	0.0165	25.3078	41.3999	AID602332
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	18.3564	0.0041	9.9848	25.9290	AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	15.8489	3.5481	19.5427	44.6684	AID743266
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	35.4813	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	20.5962	0.0046	11.3741	33.4983	AID624297
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	35.4813	0.1259	12.2344	35.4813	AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay ID	Title	Year	Journal	Article
AID443288	Growth inhibition of VHL-null human RCC4 cells after 4 days by XTT assay	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.
AID443289	Ratio of IC50 for human RCC4-VHL cells to IC50 for VHL-null human RCC4 cells	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.
AID1728168	Activation of NF-KappaB (unknown origin) expressed in SH-SY5Y cells co-transfected with pNFkappaB-Luc/pEF6 measured after 24 hrs by Bright-Glo luciferase assay relative to control	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.
AID612852	Growth inhibition of human RCC4 cells after 4 days by XTT assay	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.
AID1728167	Activation of NF-KappaB (unknown origin) expressed in SH-SY5Y cells co-transfected with pNFkappaB-Luc/pEF6 measured after 24 hrs by Bright-Glo luciferase assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.
AID612853	Growth inhibition of human RCC4/VHL cells after 4 days by XTT assay	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.
AID612854	Selectivity ratio IC50 for human RCC4/VHL cells to IC50 for human RCC4 cells	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	7 (70.00)	24.3611
2020's	2 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
stf 62247 STF 62247: has antineoplastic activity; structure in first source	2.46	2	0	substituted aniline
ptc 124 [no description available]	2.31	1	0	oxadiazole; ring assembly

Condition	Relationship Strength	Studies
Adenocarcinoma Of Kidney [description not available]	2.46	2
Angiomatosis Retinae [description not available]	2.05	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.46	2
von Hippel-Lindau Disease An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Cancer of Kidney [description not available]	2.06	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.06	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
ALS - Amyotrophic Lateral Sclerosis [description not available]	2.31	1
Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)	2.31	1

N-phenyl-4-pyridin-4-yl-2-thiazolamine

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Bioassays (22)

Research

Studies (10)

Market Indicators

Research Demand Index: 12.11

Study Types

N-phenyl-4-pyridin-4-yl-2-thiazolamine

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Bioassays (22)

Research

Studies (10)

Market Indicators

Research Demand Index: 12.11

Study Types

Related Drugs (2)

Related Conditions (12)